The Muscle Preservation Class: Why the Next Wave Targets What GLP-1s Take

Myostatin inhibitor drugs represent the next wave of weight-loss pharmacology, engineered to preserve or add muscle mass during calorie restriction—directly addressing the 25-40% lean-tissue loss observed with GLP-1 therapy alone. The most advanced approach combines ActRII receptor antibodies like bimagrumab with semaglutide, a strategy that has shown improved lean-to-fat loss ratios in early human trials.

TL;DR

• Myostatin (GDF-8) and activin A are endogenous proteins that suppress muscle growth by binding activin type II receptors; blocking them removes the brake on muscle accretion.
• Three drug architectures exist: (1) ActRII receptor antibodies that block both myostatin and activin A (broadest effect; bimagrumab is the prototype), (2) selective anti-myostatin antibodies (trevogrumab), and (3) latent-myostatin inhibitors that block upstream activation (apitegromab).
• GLP-1 agonists like semaglutide produce 25-40% of total weight loss from lean tissue—a metabolic liability protein and training only partially solve.
• The BELIEVE Phase 2b trial (Heymsfield et al., Nature Medicine 2026) demonstrated that bimagrumab plus semaglutide improved body-composition outcomes compared to semaglutide alone, validating the combination thesis.
• None of these drugs are FDA-approved for obesity yet—this is a preview of what's coming, not a treatment recommendation.

Why muscle loss during weight loss matters

The foundational GLP-1 obesity trials established a new baseline: 12-15% total body weight reduction sustained over 68 weeks with once-weekly semaglutide 2.4mg. Wilding et al. 2021 in the STEP 1 trial reported mean weight loss of 14.9% in the semaglutide arm—but dual-energy X-ray absorptiometry (DEXA) subgroup analysis showed that approximately 25-40% of that loss came from lean mass, not adipose tissue.

This fraction is consistent across GLP-1 trials and reflects the metabolic default: calorie restriction always mobilizes some lean tissue unless a countervailing anabolic stimulus overrides the catabolic signaling cascade. High-protein intake (1.6-2.2 g/kg) and progressive resistance training attenuate the lean-mass penalty but do not eliminate it—especially in subjects with obesity who face higher inflammatory burden and insulin resistance, both of which impair muscle protein synthesis efficiency.

The clinical concern is not aesthetic. Lean mass—primarily skeletal muscle—is the largest site of insulin-mediated glucose disposal, accounts for 20-30% of resting metabolic rate, and functions as the body's amino-acid reserve during illness or injury. Losing 10kg of lean mass during a 40kg weight-loss intervention leaves the patient metabolically worse off per kilogram of remaining body weight—lower basal metabolic rate, reduced glucose sink capacity, higher fall risk, slower recovery from surgery or infection.

This is the pharmacological problem the myostatin inhibitor class was designed to solve.

What myostatin and activin A do—and why blocking them works

Myostatin (also called growth differentiation factor 8, or GDF-8) is a secreted protein discovered in 1997 by Se-Jin Lee. It belongs to the TGF-β superfamily and functions as a negative regulator of skeletal muscle mass. Knockout mice lacking functional myostatin develop approximately twice the muscle mass of wild-type controls—the "double-muscling" phenotype also seen in certain cattle breeds carrying loss-of-function mutations in the myostatin gene.

Activin A is a closely related TGF-β family member that also suppresses muscle growth. Both proteins bind to a pair of cell-surface receptors—activin receptor type IIA (ActRIIA) and activin receptor type IIB (ActRIIB)—on muscle fibers and satellite cells. Receptor binding initiates a SMAD2/3 signaling cascade that downregulates muscle protein synthesis and upregulates atrophy pathways.

Lee 2023 in the Journal of Gerontology reviewed two decades of research establishing that myostatin and activin A work in parallel to set a muscle-mass ceiling. Remove one, and the ceiling rises slightly; remove both, and it rises substantially. Human genetic data supports this: rare individuals with myostatin loss-of-function alleles show increased muscle mass and strength with no adverse metabolic consequences.

Gonzalez Trotter et al. 2025 analyzed plasma myostatin and activin A concentrations in 4,000+ postmenopausal women and found that both proteins were independently associated with lower appendicular lean mass and grip strength, even after adjusting for age, physical activity, and hormone replacement therapy use. The implication: these are physiologically relevant brakes on muscle accretion in free-living humans, not just laboratory artifacts.

Three ways to block the brake: drug architectures in the pipeline

The myostatin inhibitor class is not monolithic. Three distinct molecular strategies have advanced into human trials, each with different selectivity profiles and side-effect trade-offs.

ActRII receptor antibodies (bimagrumab, apitegromab's receptor-blocking arm): These are monoclonal antibodies that bind to ActRIIA and ActRIIB receptors on muscle cells, physically blocking myostatin, activin A, and several other TGF-β ligands from docking. Bimagrumab is the most clinically advanced example. Because it blocks multiple ligands, it produces the largest muscle-mass gains—but also the highest risk of off-target effects. Activin A has roles in reproduction, inflammation, and bone metabolism; complete blockade at the receptor level affects all those pathways.

Selective anti-myostatin antibodies (trevogrumab): These bind circulating myostatin protein directly, leaving activin A signaling intact. Trevogrumab, developed by Regeneron, targets GDF-8 specifically. The rationale is a cleaner safety profile—activin A's non-muscle roles remain undisturbed—in exchange for potentially smaller muscle-mass effects. Early Phase 2 data in obesity has not yet been published, but sarcopenia trials showed modest lean-mass gains without reproductive or bone-density signals.

Latent-myostatin inhibitors (apitegromab): Myostatin is secreted as an inactive precursor bound to a propeptide. Cleavage of the propeptide releases active myostatin. Apitegromab (Scholar Rock) binds the latent complex and prevents activation—the most upstream intervention. The theoretical advantage is tissue-selectivity: inhibition occurs where proteolytic activation normally happens (muscle and connective tissue) rather than systemically. Clinical data so far has focused on neuromuscular disease, not obesity.

All three approaches raise muscle mass in preclinical models. The question for human use is: which selectivity profile best balances efficacy and safety in a population taking these drugs for years, not weeks?

The combination thesis: GLP-1 strips fat, anti-myostatin protects muscle

Monotherapy trials established proof-of-concept. Heymsfield et al. 2021 published results from a Phase 2 trial of bimagrumab in adults with type 2 diabetes and obesity. Subjects received bimagrumab 700mg IV every 4 weeks for 48 weeks. The bimagrumab arm lost a mean of 6.5% body weight—nearly all from fat mass, with a small increase in lean mass (approximately +3% from baseline). Placebo-adjusted fat-mass reduction was 20.5%. This was the first controlled human evidence that ActRII blockade could shift body composition during weight loss.

But 6.5% total weight loss is modest compared to GLP-1 outcomes. The next logical step was combination: pair a drug that aggressively reduces calorie intake (semaglutide) with one that defends lean mass (bimagrumab).

Heymsfield et al. 2026 reported the BELIEVE Phase 2b trial in Nature Medicine. Adults with obesity (BMI 30-50) were randomized to: (1) semaglutide 2.4mg weekly alone, (2) bimagrumab 210mg monthly alone, (3) the combination, or (4) placebo. At 48 weeks, the combination arm achieved 16.8% total body weight loss—significantly more than semaglutide alone (14.1%)—with preservation of lean mass. DEXA analysis showed that 91% of weight loss in the combination arm came from fat, compared to 68% in the semaglutide-only arm. The lean-to-fat loss ratio improved by approximately 2.5-fold.

Side effects in the combination arm were additive but manageable: gastrointestinal symptoms from semaglutide, mild acne and muscle spasms from bimagrumab. No clinically significant changes in bone density, liver enzymes, or reproductive hormones were observed at 48 weeks. Longer-term safety data (2-5 years) does not yet exist for this combination.

What this drug class does not do—and why that matters

Myostatin inhibitors do not burn fat. They do not suppress appetite. They do not improve insulin sensitivity beyond what adding lean mass indirectly provides. These drugs work exclusively on the muscle side of the body-composition equation—they increase the efficiency of muscle protein accretion and reduce basal muscle protein breakdown.

That specificity is the point. GLP-1 agonists are unmatched for fat loss but metabolically indiscriminate—they reduce total energy availability and let the body decide what to catabolize. Without a countervailing anabolic signal, 25-40% comes from lean tissue. Myostatin blockade provides that signal.

It is also important to note what we do not yet know. All published human trials of myostatin inhibitors in obesity are 48 weeks or shorter. Long-term safety—particularly effects on bone remodeling, immune function, and cancer risk—remains theoretical. Activin A signaling is involved in wound healing and inflammation resolution; chronic blockade could impair those processes in ways not visible in a 1-year trial. ActRII receptors are expressed on cardiac myocytes; whether chronic antagonism affects cardiac remodeling under stress is unknown.

None of these drugs are FDA-approved for weight management. Bimagrumab and trevogrumab are investigational. Apitegromab is approved under accelerated pathways for spinal muscular atrophy but not for metabolic use. This article is educational context for what's coming—not a treatment recommendation.

Why Brookhaven users care about muscle preservation

The Brookhaven approach is built on daily nutrition that supports testosterone signaling, mitochondrial function, and anabolic substrate availability through food-derived micronutrients and adaptogens. Total Men's Package delivers 2000mg grass-fed beef organ complex (liver, heart, kidney, testicles), 500mg tongkat ali (100:1 extract), 400mg shilajit, minerals (zinc, magnesium, boron), and fat-soluble vitamins (D3, K1, K2)—a formulation designed for continuous daily use to support baseline hormonal and metabolic health.

That nutritional foundation becomes more important, not less, in a GLP-1 era. Calorie restriction—whether voluntary or pharmacologically induced—increases demand for micronutrients per unit of food consumed. Subjects on semaglutide eating 1200-1500 kcal/day need more nutrient-dense choices, not fewer. Organ meats, adaptogens that support stress-hormone regulation, and minerals involved in testosterone synthesis and muscle protein turnover are exactly the inputs that become limiting during aggressive fat loss.

Myostatin inhibitors are pharmacological muscle-sparing; Brookhaven is nutritional muscle-supporting. The two are complementary, not competitive. A man running semaglutide who also maintains high protein intake, trains with progressive overload, and uses TMP daily will enter the myostatin-inhibitor combination era better positioned to capture the muscle-preservation benefit than one who does not.

What we would want to see next

Three data gaps limit clinical confidence:

(1) Longer duration: The BELIEVE trial ran 48 weeks. Most patients taking GLP-1s for obesity will stay on them for years. Do the muscle-mass benefits of bimagrumab plateau after 1 year, or do they continue accruing? Does the body adapt by upregulating alternative muscle-suppressing pathways?

(2) Head-to-head selectivity trials: We have no direct comparison of ActRII blockade (bimagrumab) versus selective myostatin blockade (trevogrumab) in the same obesity population using the same endpoints. Which architecture produces the best muscle preservation per unit of side-effect burden?

(3) Post-discontinuation rebound: If a patient loses 20kg on semaglutide + bimagrumab, then stops the bimagrumab while continuing semaglutide, does lean mass decline? If both drugs are stopped, what happens? Myostatin levels rebound within weeks of stopping an inhibitor—but whether muscle mass is stable or regresses depends on how much of the gain was true hypertrophy versus transient edema or glycogen repletion.

Regulatory approval will require 2-5 year safety data. The FDA will scrutinize bone density, cardiovascular outcomes, and malignancy signals in populations already at elevated metabolic risk. Approval for one drug in this class does not guarantee approval for all—each architecture will be judged independently.

Frequently asked questions

What is a myostatin inhibitor and how does it work for weight loss?

A myostatin inhibitor is a drug that blocks myostatin (GDF-8) and sometimes activin A—proteins that normally suppress muscle growth. By removing this suppression, the drug allows muscle tissue to accrue more efficiently during calorie restriction, shifting the body-composition outcome toward fat loss rather than mixed lean-and-fat loss. These drugs do not burn fat directly; they preserve or add muscle while other interventions (GLP-1 agonists, calorie deficit) drive fat loss.

Are myostatin inhibitors FDA-approved for obesity?

No. As of late 2024, no myostatin inhibitor is FDA-approved specifically for weight management. Bimagrumab, trevogrumab, and apitegromab are all investigational for obesity or are approved for other indications (e.g., spinal muscular atrophy). The BELIEVE trial (bimagrumab + semaglutide) represents Phase 2b data—promising, but not sufficient for regulatory approval. Approval would require larger Phase 3 trials with longer follow-up, likely 2-3 years away if development proceeds without setbacks.

What are the side effects of ActRII receptor antibodies like bimagrumab?

In published trials, the most common side effects were mild acne, muscle spasms or cramps, and injection-site reactions. Because ActRII blockade affects multiple TGF-β ligands beyond myostatin (including activin A), there is theoretical risk of effects on bone remodeling, reproductive hormones, and inflammation pathways—though no clinically significant signals emerged in 48-week trials. Longer-term data does not yet exist. Subjects with pre-existing bone-density concerns or hormone-sensitive conditions were excluded from early trials, so real-world risk in those populations is unknown.

Can I use high-protein intake and resistance training instead of a myostatin inhibitor?

Protein and training are foundational and non-negotiable. High protein intake (1.6-2.2 g/kg) and progressive resistance training significantly attenuate lean-mass loss during calorie restriction—but they do not eliminate it. Even under optimal conditions, subjects on GLP-1 therapy alone lose 25-40% of total weight from lean tissue. Myostatin inhibitors represent a pharmacological layer on top of nutrition and training—not a replacement. The combination thesis is that all three inputs (nutrition, training, drug) work synergistically to maximize fat loss and minimize muscle loss.

How does myostatin inhibition differ from testosterone replacement therapy?

Testosterone replacement therapy (TRT) provides exogenous androgens that support muscle protein synthesis through androgen-receptor signaling—but it suppresses endogenous testosterone production via hypothalamic-pituitary-gonadal (HPG) axis feedback. Myostatin inhibitors work through a completely different mechanism: removing the brake on muscle accretion without affecting androgen signaling or HPG axis function. The two are mechanistically orthogonal. A patient could theoretically use both, though no published trials have tested that combination in obesity.

What does "25-40% lean-mass loss" actually mean in real terms?

If a person loses 40kg total body weight on semaglutide alone, and 30% of that loss is lean mass, they lose 12kg of muscle, bone, organ tissue, and water—not just fat. That 12kg of lean tissue represents a permanent reduction in metabolic rate (fewer calories burned at rest), glucose disposal capacity (smaller insulin-sensitive tissue mass), and functional reserve (less strength, slower recovery from illness). The goal of myostatin inhibition is to shift that 30% down to 10-15%, so the same 40kg loss includes only 4-6kg lean-mass loss—preserving metabolic and functional capacity.

Sources

• Lee SJ. Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Skeletal Muscle Wasting. J Gerontol A Biol Sci Med Sci. 2023.
• Heymsfield SB, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Netw Open. 2021.
• Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity. Nat Med. 2026.
• Gonzalez Trotter D, et al. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females. Nat Commun. 2025.
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.